Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
NRG Oncology
NRG Oncology
Instituto Oncoclinicas
Instituto Nacional de Cancer, Brazil
Mucosa Innovations, S.L.
University of California, Irvine
Chiayi Christian Hospital
German University in Cairo
University of Pennsylvania
West China Hospital
Stony Brook University
MitoImmune Therapeutics
University of Barcelona
Fundacion Clinica Valle del Lili
Taipei Medical University
University Hospital Schleswig-Holstein
EpicentRx, Inc.
EpicentRx, Inc.
MuReva Phototherapy Inc.
First Affiliated Hospital of Guangxi Medical University
Sun Yat-sen University
Institut de cancérologie Strasbourg Europe
Ottawa Hospital Research Institute
West China Hospital
Northwell Health
Kaohsiung Medical University Chung-Ho Memorial Hospital
University of Santiago de Compostela
AronPharma Sp. z o. o.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Monopar Therapeutics
Chinese University of Hong Kong
Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
Aziende Chimiche Riunite Angelini Francesco S.p.A
Soligenix
NeoMedLight
Galera Therapeutics, Inc.
University of Louisville
University Hospital, Basel, Switzerland
Chang Gung Memorial Hospital
Cyprus University of Technology
Santalis Pharmaceuticals, Inc.
Prince of Songkla University
Chang Gung Memorial Hospital
University of California, San Francisco
CSL Behring
NeoMedLight
Taipei Medical University
NYU Langone Health
University of Miami
National University Hospital, Singapore
Innovation Pharmaceuticals, Inc.